Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 475

1.

Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder.

Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M.

J Clin Psychiatry. 2005 Mar;66(3):353-9.

PMID:
15766302
2.

Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.

Koran LM, Aboujaoude E, Gamel NN.

J Clin Psychiatry. 2009 Nov;70(11):1530-5. doi: 10.4088/JCP.08m04605. Epub 2009 Jun 30.

PMID:
19573497
3.
4.

Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

Aboujaoude E, Barry JJ, Gamel N.

J Clin Psychopharmacol. 2009 Feb;29(1):51-5. doi: 10.1097/JCP.0b013e318192e9a4.

PMID:
19142108
5.

Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.

Pallanti S, Quercioli L, Koran LM.

J Clin Psychiatry. 2002 Sep;63(9):796-801.

PMID:
12363120
6.

Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.

Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A.

J Clin Psychiatry. 2005 Jan;66(1):73-9.

PMID:
15669891
7.
8.

Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.

Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN.

J Clin Psychiatry. 2005 Apr;66(4):515-20.

PMID:
15816795
9.

Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.

Simpson HB, Gorfinkle KS, Liebowitz MR.

J Clin Psychiatry. 1999 Sep;60(9):584-90.

PMID:
10520976
10.

Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.

Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR.

J Clin Psychiatry. 2005 Jun;66(6):736-43.

PMID:
15960567
11.

A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.

Denys D, van Megen HJ, van der Wee N, Westenberg HG.

J Clin Psychiatry. 2004 Jan;65(1):37-43.

PMID:
14744166
12.

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.

Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F.

J Clin Psychopharmacol. 2008 Oct;28(5):550-4. doi: 10.1097/JCP.0b013e318185e735.

PMID:
18794652
13.

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.

McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH.

Arch Gen Psychiatry. 1994 Apr;51(4):302-8.

PMID:
8161290
14.
15.

Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.

Alonso P, Menchon JM, Pifarre J, Mataix-Cols D, Torres L, Salgado P, Vallejo J.

J Clin Psychiatry. 2001 Jul;62(7):535-40.

PMID:
11488364
16.

Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.

Bergeron R, Ravindran AV, Chaput Y, Goldner E, Swinson R, van Ameringen MA, Austin C, Hadrava V.

J Clin Psychopharmacol. 2002 Apr;22(2):148-54.

PMID:
11910259
17.

Citalopram for treatment-resistant obsessive-compulsive disorder.

Pallanti S, Quercioli L, Paiva RS, Koran LM.

Eur Psychiatry. 1999 Apr;14(2):101-6.

PMID:
10572334
18.

A 2-year study of sertraline in the treatment of obsessive-compulsive disorder.

Rasmussen S, Hackett E, DuBoff E, Greist J, Halaris A, Koran LM, Liebowitz M, Lydiard RB, McElroy S, Mendels J, O'Connor K.

Int Clin Psychopharmacol. 1997 Nov;12(6):309-16.

PMID:
9547132
19.

Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial.

Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J.

Eur Neuropsychopharmacol. 2000 May;10(3):165-9.

PMID:
10793318
20.

High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.

Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, Robinson DG, Crits-Christoph P, Mandel FS, Austin C.

J Clin Psychiatry. 2006 Jan;67(1):15-22.

PMID:
16426083

Supplemental Content

Support Center